TY - JOUR T1 - Denosumab: A novel antiresorptive drug for osteoporosis JF - Cleveland Clinic Journal of Medicine JO - Cleve Clin J Med SP - 105 LP - 114 DO - 10.3949/ccjm.82a.13173 VL - 82 IS - 2 AU - Ernest Suresh AU - Bo Abrahamsen Y1 - 2015/02/01 UR - http://www.ccjm.org/content/82/2/105.abstract N2 - Denosumab is a novel antiresorptive drug that has been approved for use as a first-line drug for primary and secondary prevention of osteoporotic fractures. The authors discuss the mechanism of action of denosumab, review the evidence for its efficacy and safety in patients with osteoporosis, and offer recommendations for its use in clinical practice. ER -